Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies December 17, 2020 03:00 PM Eastern Standard Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced [...]
Ology Bioservices, Inc. Strategic Partner for Bioanalytical Testing Pharma Tech Outlook - November 23, 2020 Ology Bioservices, Inc. (Ology Bio) is a US based, biologics-focused, full-service contract development and manufacturing organization (CDMO). The company has [...]
Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail November 23, 2020 08:00 AM Eastern Standard Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract [...]
Ology Bioservices Named 2020 Company of the Year by BioFlorida October 30, 2020 01:12 PM Eastern Daylight Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today [...]
Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate October 27, 2020 08:30 AM Eastern Daylight Time ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract [...]
MasterControl Recognizes Customers’ Achievements The first annual Masters of Excellence Awards highlights customer success October 22, 2020 08:00 ET | Source: MasterControl Inc. SALT LAKE CITY, Oct. 22, 2020 (GLOBE NEWSWIRE) -- MasterControl, a provider of software solutions [...]
Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
The NANO-ADM (Advanced Development and Manufacturing) facility, as it is known, will expand Nanotherapeutics’ core competencies in the development and cGMP manufacture of preclinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.
Tomic MT, Espinoza Y, Martinez Z, et al. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins 2019, 11(4), 208; https://doi.org/10.3390/toxins11040208.
Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894.